Drug Trial Radar · NCT01159028
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
Last checked: Nov 19, 2026Latest source record: May 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 2010
Primary completion
Mar 30, 2017
Study completion Mar 30, 2017
Sponsor
- Lead sponsor
- Bio-Path Holdings, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The first goal of this clinical research study is to find the highest safe dose of BP1001, a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS), for patients with Philadelphia Chromosome positive CML, AML, ALL and MDS. The response of the leukemia to this treatment will also be studied. The second goal of this clinical research study is to evaluate the safety and toxicity of the combination of BP1001 and concurrent low-dose ara-C (LDAC) in patients with AML.
Conditions
- Recurrent Adult Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome
- Ph1 Positive CML
Interventions
BP1001Drug
Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
BP1001 in combination with LDACDrug
Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of BP1001Time frame: 30 days
- Safety of BP1001 in combination with LDACTime frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M. D. Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.